Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
MGD024 is an investigational, next-generation, bispecific CD123 × CD3 DART® molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML). MGD024 was designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life.
Clinical Development
Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on MGD024.
Our Rights
In October 2022, MacroGenics announced that it had entered into an exclusive option and collaboration agreement with Gilead to develop MGD024 and two additional bispecific research programs. MacroGenics is responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. MacroGenics received an upfront payment and will be eligible to receive target nomination, option fees, and milestone payments. MacroGenics will also be eligible to receive royalties on worldwide net sales of MGD024 and products under the two research programs. (Learn More: Gilead collaboration)
Clinical Trials
Presentations & Publications
Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.